Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study

Niu, Quan; Lu, Youyi; Xu, Shigao; Shi, Qun; Guo, Binhui; Guo, Zhe; Huang, Ting; Wu, Yinxia; Yu, Junjie

doi:10.2147/cmar.s175286

Cited by 22 publications

(32 citation statements)

References 28 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SEER extent of disease is categorized into localized, regional, and distant disease. Localized tumour, regional tumour and distant disease are defined as previously reported [8][9][10][11]. Five-year survival rates were calculated using Kaplan-Meier analysis, calculating overall survival (OS) and calculating diseasespecific survival (CSS) rates [12].…”

Section: Methodsmentioning

confidence: 99%

Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015

Huang

Hong

Meng

et al. 2020

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background: Malignant fibrous neoplasms (MFN) of long bones are rare lesions. Moreover, the prognostic determinants of MFN of long bones have not been reported. This study aimed to present epidemiological data and analyse the prognostic factors for survival in patients with MFN. Materials and methods: The Surveillance, Epidemiology, and End Results (SEER) programme database was used to screen patients with malignant fibrous neoplasms (MFN) of long bones from 1973 to 2015, with attention to fibrosarcoma, fibromyxosarcoma, periosteal fibrosarcoma and malignant fibrous histiocytoma. The prognostic values of overall survival (OS) and cancer-specific survival (CSS) were assessed using the Cox proportional hazards regression model with univariate and multivariate analyses. The Kaplan-Meier method was used to obtain OS and CSS curves. Results: A total of 237 cases were selected from the SEER database. Malignant fibrous histiocytoma was the most common form of lesion in long bones. Multivariate analysis revealed that independent predictors of OS included age, stage, tumour size and surgery. Age, stage, tumour size and surgery were also independent predictors of CSS. Additionally, the most significant prognostic factor was whether metastasis had occurred at the time of initial diagnosis. Conclusion: Among patients with MFN of long bones, age (> 60 years), tumour size (> 10 cm), distant stage, and non-surgical treatment are factors for poor survival.

show abstract

Section: Methodsmentioning

confidence: 99%

Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015

Huang

Hong

Meng

et al. 2020

BMC Musculoskelet Disord

View full text Add to dashboard Cite

show abstract

“…These finding validate those of Niu et al, from within a previous version of the SEER database. 14 16 However, the SEER database does not discriminate between either adjuvant or neoadjuvant CHT. As a consequence, it is possible that a proportion of NC patients who underwent RC with CHT in the present study received adjuvant CHT.…”

Section: Discussionmentioning

confidence: 99%

Adherence to guideline recommendations for multimodality treatment of patients with pT2–3 M0 non‐urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes

et al. 2020

View full text Add to dashboard Cite

Abbreviations & Acronyms AC = adenocarcinoma CHT = chemotherapy CSM = cancer-specific mortality EAPC = estimating annual percentage changes HR = hazard ratio ICD-O = international classification of disease for oncology IQR = interquartile range LNI = lymph node invasion MMT = multimodality treatment NC = neuroendocrine carcinoma NCCN = National Comprehensive Cancer Network NCDB = national cancer database OM = overall mortality RC = radical cystectomy RT = radiotherapy SCC = squamous cell carcinoma SEER = Surveillance, Epidemiology and End Results UCUB = urothelial carcinoma of the urinary bladder Correspondence: Francesco A Mistretta M.D., Cancer Prognostics and Health Outcomes Unit,Objectives: To analyze contemporary multimodality treatment rates, defined as radical cystectomy plus chemotherapy and/or radiotherapy, for pT2-3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients. Additionally, we tested for the effect of multimodality treatment versus radical cystectomy alone on cancer-specific mortality. Methods: Within the Surveillance, Epidemiology and End Results database (2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015), 887 pT2-3 any N-stage M0 non-urothelial carcinoma of urinary bladder patients treated with radical cystectomy were identified. Kaplan-Meier plots, and univariable and multivariable Cox regression analyses focused on cancer-specific mortality rates. Results: Squamous cell carcinoma was recorded in 499 (56.3%) patients, neuroendocrine carcinoma in 246 (27.7%) and adenocarcinoma in 142 (16.0%). The highest proportion of multimodality treatment patients was recorded in neuroendocrine carcinoma (69.1%), relative to adenocarcinoma (34.5%) and squamous cell carcinoma (26.4%). A statistically significant annual increase was recorded in multimodality treatment rates in neuroendocrine carcinoma patients (46.7-74.2%, P < 0.01), but not in adenocarcinoma or squamous cell carcinoma patients. The 5-year cancer-specific mortality rate in neuroendocrine carcinoma patients was significantly lower after multimodality treatment versus radical cystectomy alone (37.0% vs 51.5%; P < 0.01), but no statistically significant differences were recorded in both adenocarcinoma (46.1% vs 35.5%; P = 0.8) and squamous cell carcinoma (41.4% vs 31.1%; P = 0.8) patients. In multivariable analyses, for neuroendocrine carcinoma patients, multimodality treatment was an independent predictor of a lower cancer-specific mortality rate (hazard ratio 0.58, P = 0.03). Conclusions: Multimodality treatment has been increasingly used during the study period in neuroendocrine carcinoma patients, and it has translated into a cancer-specific mortality benefit. This is not the case for other non-urothelial carcinoma of urinary bladder patients, such as adenocarcinoma or squamous cell carcinoma.

show abstract

“…The frequency data were stratified by sex, age, race, tumor size, grade, SEER extent of disease and treatment strategy. The SEER extent of disease is classified into localized, regional, and distant disease, as previously reported …”

Section: Methodsmentioning

confidence: 99%

Nomograms Predict Cancer‐Specific and Overall Survival of Patients With Primary Limb Leiomyosarcoma

Wang

Hong

Meng

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

To date, there have been no data to predict the survival of patients with leiomyosarcoma from soft limb tissue because of the rarity of this disease. Nomograms have been widely applied in clinical oncology to precisely predict the survival of individual patients. This was a retrospective study to construct and validate nomograms to predict the cancer-specific survival (CSS) and overall survival (OS) of patients with primary limb leiomyosarcoma (PL-LMS). A total of 1,208 patients with LMS from limb soft tissue were collected from the Surveillance, Epidemiology, and End Results database from 1975 to 2015. We identified independent prognostic factors using univariate and multivariate Cox analyses. These prognostic factors were then included in the nomograms to predict 3-and 5-year CSS and OS rates. Finally, we validated the nomograms internally and externally. A total of 1208 patients were collected and divided into validation (N = 604) and training (N = 604) groups. Age, race, grade, tumor size, stage, and surgical types were demonstrated as independent prognostic factors for CSS and OS (all p < 0.05) and further used to construct the nomograms. The concordance index (C-index) for CSS was 0.857 for internal validation and 0.727 for external validation. The C-index for OS and CSS both demonstrated that the nomogram prediction agreed perfectly with actual survival. We developed nomograms to predict CSS and OS in PL-LMS patients and can benefit from using them to identify patients' mortality risk and make more precise assessments regarding survival.

show abstract

Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study

Cited by 22 publications

References 28 publications

Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015

Malignant fibrous neoplasms of long bones: analysis of the surveillance, epidemiology, and end results database from 1973 to 2015

Adherence to guideline recommendations for multimodality treatment of patients with pT2–3 M0 non‐urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes

Nomograms Predict Cancer‐Specific and Overall Survival of Patients With Primary Limb Leiomyosarcoma

Contact Info

Product

Resources

About